 |
| (c) eyerounds.org |
Is there an increased risk for tractional retinal detachment (TRD) in proliferative diabetic retinopathy (PDR) associated with intravitreal injections alone compared with other treatment regimens? That's the question that researchers at Perelman School of Medicine at the University of Pennsylvania sought an answer for.
This nested case-control study included data from January 1, 2000, to June 30, 2021, of patients with PDR. Those who progressed to TRD were matched to non-TRD controls up to a 5:1 ratio. Exclusion criteria included 2 or fewer years in the plan, history of nondiabetic retinopathy, vitreous hemorrhage, previous RD, or any other surgically indicated diagnosis. Patient data were obtained from a deidentified commercial and Medicare Advantage medical claims database. Statistical analysis was performed from January to May 2022.
After application of inclusion and exclusion criteria, a total of 214 patients (mean [SD] age, 55.6 [12.4] years; 115 female [53.7%]) with PDR and TRD were matched to 978 controls (mean [SD] age, 65.6 [11.3] years; 507 female [51.8%]) with only PDR. Among patients with TRD, 69 (32.2%) were treated with laser only, 17 (7.9%) were treated with injection only, 39 (18.2%) were treated with both, and 89 (41.6%) had no prior treatment. Among patients in the PDR-only group, 207 (21.2%) received laser only, 83 (8.5%) received injection only, 57 (5.8%) received both, and 631 (64.5%) received no treatment. After adjusted analysis, no difference in odds of TRD for patients who received injection only compared with patients who received laser only was found (adjusted OR [aOR], 0.56; 95% CI, 0.27-1.14). Patients who received both treatments had higher odds of TRD compared with those who received laser only (aOR, 2.33; 95% CI, 1.21-4.48), and patients who had no treatment had lower odds of TRD (aOR, 0.46; 95% CI, 0.29-0.71; P < .001 for treatment category). Similarly, no difference was seen in the odds of TRD between those with LTFU for 6 months or longer and those without LTFU (aOR, 0.72; 95% CI, 0.49-1.07; P = .11).
Since you’re here...we have a small favor to ask. Retina Global is a nonprofit, and we have to depend on your support to sustain the work we do. Hence the need to ask for your help. Retina Global's work is important, since it not only provides help to disadvantaged people, but also provides resources for developing new treatments that can potentially cure blindness. What we do takes a lot of time, money and hard work. But we do it because we believe we have to help stop someone somewhere from going blind. So make a difference. Click here to donate. Your support is much appreciated. Thank you!
Results of this case-control analysis suggest that there is no increased risk of TRD associated with IVI-only treatment or with 6-month or longer periods of LTFU, which supports the findings of other investigations. Nonetheless, LTFU rates continue to remain high in patients with PDR, which can contribute to substantial vision loss regardless of treatment regimen.
Since you’re here...we have a small favor to ask. Retina Global is a nonprofit, and we have to depend on your support to sustain the work we do. Hence the need to ask for your help. Retina Global's work is important, since it not only provides help to disadvantaged people, but also provides resources for developing new treatments that can potentially cure blindness. What we do takes a lot of time, money and hard work. But we do it because we believe we have to help stop someone somewhere from going blind. So make a difference. Click here to donate. Your support is much appreciated. Thank you!
Results of this case-control analysis suggest that there is no increased risk of TRD associated with IVI-only treatment or with 6-month or longer periods of LTFU, which supports the findings of other investigations. Nonetheless, LTFU rates continue to remain high in patients with PDR, which can contribute to substantial vision loss regardless of treatment regimen.
Source: Published in JAMA Ophthalmology. Click here to read the full article.
No comments:
Post a Comment
Thanks for your comments. We will get back to you shortly if there is a need to respond to it.
- Admin, Retina Global
Read more on Retina Global.